Covid-19 roundup: Moderna vaccine kicks up antibodies against Delta variant; UK study validates mix-and-match approach for Pfizer-AstraZeneca
In an continued effort to monitor the effectiveness of its Covid-19 vaccine, Moderna has rolled out the latest slate of neutralization data against different variants — including the Delta variant first identified in India.
The data were published on the preprint server bioRxiv as the Delta variant has engulfed a number of countries, leading to resurgence of infections.
Deploying a well-documented method, investigators took blood samples from eight participants of Moderna’s Phase I trial one week after their second dose of mRNA-1273, and pitted them against pseudovirus engineered to bear features of variants of concerns (VOCs), including the “the Beta variant (B.1.351, first identified in South Africa), three lineage variants of B.1.617 (first identified in India), including the Kappa (B.1.617.1) and the Delta variants (B.1.617.2); the Eta variant (B.1.525, first identified in Nigeria); and the A.23.1 and A.VOI.V2 variants first identified in Uganda and Angola, respectively.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
